analyt
perform
respi
test
laboratori
turku
finland
evalu
use
nucleic
acid
amplif
techniqu
naat
gold
standard
maripoc
assay
allow
autom
detect
antigen
respiratori
virus
influenza
b
virus
respiratori
syncyti
viru
adenoviru
human
metapneumoviru
parainfluenza
virus
posit
result
sampl
high
viral
load
avail
min
nasopharyng
aspir
n
patient
acut
respiratori
infect
previous
posit
sampl
analyz
maripoc
naat
simplexa
tm
fluaflub
rsv
kit
n
respiratori
viru
panel
rvp
fast
n
sensit
specif
posit
predict
valu
neg
predict
valu
maripoc
respect
posit
result
report
min
good
analyt
perform
extend
portfolio
maripoc
show
rapid
assay
good
altern
etiolog
diagnosi
acut
respiratori
infect
laboratori
equip
molecular
assay
acut
respiratori
infect
ari
viral
etiolog
lead
caus
medic
demand
age
group
repres
signific
overload
healthcar
system
although
major
infect
selflimit
mild
sever
infect
occur
mainli
young
children
elderli
immunosupress
individu
patient
underli
diseas
influenza
flu
b
virus
respiratori
syncyti
viru
rsv
parainfluenzavirus
piv
adenoviru
adv
rhinoviru
rhv
enteroviru
ev
human
coronaviru
cov
classic
respiratori
pathogen
associ
ari
atmar
et
al
creer
et
al
dimopoulo
et
al
henderson
et
al
jen
et
al
ruuskanen
et
al
yun
et
al
well
current
describ
virus
human
metapneumoviru
hmpv
van
den
hoogen
et
al
sarscov
ksiazek
et
al
cov
van
der
hoek
et
al
woo
et
al
merscov
zaki
et
al
human
bocaviru
bov
alland
et
al
other
ruuskanen
et
al
clinic
manifest
ari
nonspecif
although
season
pattern
viru
activ
could
orient
etiolog
diagnosi
sever
virus
cocircul
time
throughout
year
ruuskanen
et
al
rapid
etiolog
diagnosi
ari
improv
patient
manag
allow
appropri
ontim
antivir
therapi
demonstr
reduct
complic
durat
symptom
hospit
stay
dheilli
et
al
fior
et
al
inde
rapid
diagnosi
avoid
use
unnecessari
antibiot
ancillari
diagnost
studi
ferronato
et
al
et
al
respi
test
maripoc
arcdia
intern
oy
ltd
turku
finland
allow
autom
antigen
detect
differenti
respiratori
virus
flu
flu
b
rsv
adv
hmpv
piv
piv
piv
streptococcu
pneumonia
antigen
sandwich
captur
antibodi
fluoresc
label
antibodi
conjug
onto
polym
microspher
form
immunocomplex
proport
concentr
antigen
sampl
fluoresc
signal
individu
microspher
measur
separationfre
assay
method
base
excit
fluoresc
detect
technolog
arcdia
koskinen
et
al
system
automat
report
preliminari
result
min
sampl
high
viral
load
final
result
hour
instrument
allow
semicontinu
load
everi
min
time
take
sampl
process
sampl
load
instrument
run
aim
studi
evalu
analyt
perform
maripoc
detect
respiratori
virus
clinic
sampl
compar
rapid
antigen
detect
test
rdt
nucleic
acid
amplif
techniqu
naat
nasopharyng
aspir
npa
patient
clinic
suspicion
ari
viral
etiolog
attend
univers
hospit
virgen
de
la
niev
prospect
collect
analyz
parallel
maripoc
routin
method
januari
april
sampl
separ
aliquot
one
routin
viral
test
anoth
maripoc
analysi
third
one
refriger
hour
frozen
hour
analysi
necessari
addit
npa
store
previous
posit
respiratori
virus
includ
includ
maripoc
retrospect
analyz
calcul
sensit
specif
predict
valu
tube
ml
respiratori
tract
infect
rti
sampl
buffer
suppli
kit
arcdia
intern
oy
ltd
inocul
fresh
npa
prospect
studi
vortex
twice
sec
centrifug
min
g
insert
maripoc
system
concentr
step
appli
frozen
sampl
retrospect
studi
order
minim
deleteri
effect
freezingthaw
sensit
follow
ml
sampl
centrifug
min
rpm
supernat
discard
pellet
ad
tube
contain
rti
sampl
buffer
rdt
simplexa
perform
sampl
patient
attend
emerg
unit
naat
simplexa
andor
luminex
carri
sampl
hospit
individu
rdt
neg
done
evalu
analyt
perform
maripoc
naat
use
refer
techniqu
viral
strain
titrat
tissu
cultur
infecti
dose
tcid
assay
viral
strain
obtain
clinic
isol
propag
appropri
cell
line
flu
b
rsv
adv
hmpv
cell
incub
day
cytopath
effect
cpe
observ
cell
monolay
harvest
aliquot
preserv
liquid
nitrogen
use
tcid
assay
perform
viru
describ
hsiung
appear
cpe
examin
daili
day
postinfect
tcid
calcul
use
method
hamilton
et
al
lod
maripoc
separ
calcul
virus
includ
panel
tenfold
serial
dilut
titrat
strain
tcid
prepar
quadrupl
physiolog
salin
steril
solut
maripoc
assay
carri
dilut
ad
ml
rti
sampl
buffer
describ
lod
defin
lowest
dilut
express
tcid
gave
posit
result
repetit
studi
protocol
carri
accord
declar
helsinki
nonintervent
studi
addit
investig
routin
procedur
biolog
materi
use
standard
viral
diagnost
follow
physician
prescript
addit
sampl
modif
routin
sampl
protocol
perform
data
analys
carri
use
anonym
databas
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
confid
interv
ci
maripoc
separ
calcul
viru
regardless
detect
viru
sampl
cohen
kappa
coeffici
agreement
spss
softwar
spss
chicago
il
usa
maripoc
rdt
flu
flu
b
rsv
naat
calcul
total
npa
pediatr
adult
patient
analyz
pediatr
individu
age
year
old
mean
sd
median
patient
year
old
age
year
old
mean
sd
median
pneumonia
detect
maripoc
sampl
children
adult
respect
least
respiratori
viru
detect
pneumoniaeposit
pneumoniaeneg
sampl
respect
maripoc
manufactur
recommend
report
result
patient
younger
year
high
percentag
colon
microorgan
could
expect
studi
sampl
pediatr
patient
younger
year
old
thu
pneumonia
includ
data
analysi
prospect
studi
carri
fresh
sampl
children
adult
retrospect
studi
includ
npa
children
adult
overal
virus
sampl
detect
maripoc
two
virus
detect
sampl
remain
maripocneg
specimen
naat
yield
neg
result
virus
includ
maripoc
neg
posit
virus
includ
maripoc
panel
rhvev
cov
bov
luminex
simplexa
carri
subset
sampl
respect
result
method
consid
togeth
naat
result
comparison
maripoc
overal
sensit
specif
ppv
npv
maripoc
respect
tabl
maripoc
assay
fail
detect
virus
flu
n
flu
b
n
rsv
n
adv
n
hmpv
n
piv
n
inde
falseposit
result
adv
n
piv
n
rsv
n
detect
maripoc
sampl
sampl
virus
codetect
maripoc
virus
identifi
refer
method
flu
b
n
piv
n
falseposit
result
report
preliminarili
trueposit
result
avail
min
codetect
virus
includ
maripoc
panel
observ
sampl
refer
method
sampl
maripoc
panel
detect
virus
lowest
sensit
maripoc
obtain
hmpv
adv
piv
rdt
flu
rsv
perform
sampl
respect
tabl
discord
result
maripoc
rdt
resolv
naat
show
falseneg
result
maripoc
rdt
respect
maripoc
assay
fail
detect
flu
rsv
wherea
rdt
detect
flu
b
rsv
excel
agreement
maripoc
obtain
compar
rdt
k
index
ci
naat
k
index
ci
lowest
lod
maripoc
obtain
hmpv
follow
adv
flu
b
rsv
flu
yield
highest
lod
assess
tcid
tabl
naat
becom
gold
standard
etiolog
diagnosi
ari
sinc
sensit
viral
cultur
antigen
detect
assay
current
mani
commerci
multiplex
molecular
assay
develop
allow
partial
complet
autom
procedur
mahoni
howev
use
clinic
set
pointofcar
method
still
limit
part
due
higher
cost
andor
handson
time
wishaupt
et
al
renaud
rdt
prove
util
referr
pointofcar
diagnost
assay
mainli
rsv
flu
greatest
impact
health
system
howev
sensit
may
vari
depend
method
type
patient
sampl
cdc
lieberman
et
al
utokaparch
et
al
assay
also
use
detect
respiratori
virus
hmpv
matsuzaki
et
al
adv
fujimoto
et
al
et
al
variabl
sensit
thu
routin
investig
latter
virus
rdt
consid
costeffect
pointofcar
approach
sinc
lead
signific
increas
cost
cumbersom
process
respiratori
sampl
emerg
set
maripoc
assay
repres
multiplex
antigen
detect
method
would
serv
pointofcar
assay
sinc
highli
posit
result
avail
min
minim
handson
time
process
present
studi
sensit
maripoc
compar
naat
rsv
flu
flu
b
respect
furthermor
maripoc
detect
flu
b
sampl
rsv
sampl
confirm
refer
method
test
neg
rdt
previou
studi
evalu
maripoc
report
similar
result
rsv
flu
detect
broton
et
al
ivaska
et
al
tuuminen
et
al
obtain
higher
sensit
flu
previou
studi
report
valu
rang
broton
et
al
ivaska
et
al
tuuminen
et
al
sever
paramet
detect
method
use
comparison
sampl
type
andor
studi
popul
might
influenc
differ
studi
sampl
children
year
old
data
shown
work
tuuminen
et
al
children
anoth
antigen
detect
method
use
comparison
previous
report
chartrand
et
al
antigen
detect
method
less
sensit
flu
adult
inde
use
npa
studi
conduct
nasopharyng
swab
ivaska
et
al
tuuminen
et
al
previou
report
assess
detect
rate
respiratori
virus
greater
npa
nasopharyng
swab
meerhoff
et
al
antigen
detect
test
adv
base
immunochromatographi
shown
variabl
analyt
result
et
al
report
moder
sensit
low
specif
compar
viral
cultur
lower
sensit
compar
naat
wherea
fujimoto
et
al
found
specif
sensit
compar
viral
cultur
naat
respect
studi
maripoc
yield
sensit
specif
adv
detect
compar
naat
evalu
maripoc
detect
adv
hmpv
piv
hamper
low
number
posit
seri
matsuzaki
et
al
obtain
sensit
specif
hmpv
antigen
detect
test
compar
realtim
revers
transcriptasepolymeras
chain
reaction
similar
result
report
studi
advantag
maripoc
rdt
hmpv
adv
piv
detect
multiplex
also
allow
simultan
detect
virus
major
impact
health
system
ie
flu
rsv
high
specif
maripoc
observ
virus
analyz
sinc
falseposit
result
obtain
furthermor
sampl
anoth
respiratori
viru
correctli
identifi
preliminari
report
thu
patient
would
wrongli
classifi
viral
respiratori
infect
although
molecular
assay
repres
gold
standard
diagnos
viral
ari
nucleic
acid
respiratori
virus
asymptomat
individu
demonstr
jansen
et
al
furthermor
naat
usual
associ
longer
respons
time
higher
cost
use
pointofcar
antigen
detect
method
healthcar
set
demonstr
clinic
benefit
et
al
dheilli
et
al
ferronato
et
al
rapid
detect
viral
respiratori
pathogen
also
import
take
appropri
isol
measur
confirm
case
order
prevent
nosocomi
outbreak
especi
flu
rsv
epidem
calcul
lod
maripoc
viru
tcid
paramet
indic
viral
infect
lod
maripoc
flu
tcid
viral
load
respiratori
secret
reach
maximum
day
postinfect
yezli
otter
maripoc
use
sampl
lod
flu
viru
correspond
tcid
one
third
tcid
calcul
amount
might
expect
present
respiratori
sampl
infect
individu
mean
titer
tcid
ml
rsv
report
infect
infant
time
hospit
admiss
hall
et
al
lod
maripoc
viru
tcid
thu
sampl
contain
approxim
tcid
yield
good
sensit
assay
rsv
detect
obtain
lowest
lod
maripoc
hmpv
viru
grow
slightli
viral
cultur
deffrasn
et
al
thu
calcul
tcid
could
accur
indic
viru
amount
cell
cultur
consequ
respiratori
sampl
report
low
dose
rang
tcid
adv
necessari
caus
infect
yezli
otter
result
obtain
work
minimum
tcid
adv
present
respiratori
sampl
give
posit
maripoc
result
amount
within
rang
viru
titer
present
respiratori
sampl
infect
individu
highest
lod
lowest
sensit
demonstr
piv
find
data
amount
piv
respiratori
tract
follow
infect
inde
low
number
sampl
test
allow
conclus
howev
sensit
maripoc
piv
optim
sensit
obtain
virus
show
assay
may
optim
pointofcar
approach
diagnosi
viral
ari
probabl
best
singl
method
laboratori
equip
molecular
assay
one
limit
studi
may
viral
strain
dilut
salin
solut
virusspikedneg
npa
would
taken
account
possibl
deleteri
effect
sampl
lod
valu
except
certain
respiratori
tract
compon
present
dilut
viral
strain
similar
matrix
could
expect
mani
npa
sampl
variabl
amount
salin
solut
case
result
obtain
confirm
good
perform
maripoc
viral
infecti
dose
clinic
specimen
minimum
turnaround
time
virolog
method
min
rdt
h
naat
h
viral
cultur
maripoc
system
report
trueposit
result
min
maripoc
assay
rapid
easi
specif
method
multiplex
detect
main
respiratori
virus
involv
ari
good
analyt
perform
extend
portfolio
maripoc
show
rapid
assay
good
altern
etiolog
diagnosi
acut
respiratori
infect
laboratori
equip
molecular
assay
